GLP-1 Agonists Cut PAD Risks in Type 2 Diabetes
GLP-1 receptor agonists like semaglutide were linked to a 48% lower amputation risk and 36% fewer leg artery procedures versus metformin in type 2 diabetes with PAD. Benefits were strongest in severe PAD and obesity.









